Avalo CFO exercises options, sells 12K shares
Avalo Therapeutics’ chief financial officer exercised options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 12,394 shares of common stock on September 16, 2026 at an exercise price of $9.88 per share and sold the same number of shares at a weighted-average price of $16.33 per share. The transactions were carried out under a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, Sullivan held 83,848 options to purchase additional shares of Avalo Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 12,394 shares ($80K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Sullivan Christopher Ryan
Role
Chief Financial Officer
Sold
12,394 shs ($202K)
Approx. gross sale proceeds
$202K
Approx. exercise cost
$122K
Approx. pre-tax spread
$80K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 12,394 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 12,394 | $9.88 | $122K |
| Sale | Common Stock F1, F2 | 12,394 | $16.3335 | $202K |
Holdings After Transaction:
Stock Option (Right to Buy) — 83,848 contracts (Direct);
Common Stock — 39,900 shares (Direct)
Footnotes (3)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
- F2. The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3. The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Options exercised: 12,394 shares
Option exercise price: $9.88 per share
Shares sold: 12,394 shares
+5 more
8 metrics
Options exercised
12,394 shares
Stock options for common stock exercised on September 16, 2026
Option exercise price
$9.88 per share
Exercise price for 12,394 stock options
Shares sold
12,394 shares
Common shares sold on September 16, 2026
Weighted-average sale price
$16.33 per share
Weighted-average price for the reported share sales within a range of $15.91 to $16.65
Remaining options
83,848 options
Stock options held after the reported exercise
Rule 10b5-1 plan adoption date
May 18, 2026
Date the trading plan governing these transactions was adopted
Initial vesting portion
25%
Portion of the option that vests on March 28, 2025
Subsequent vesting period
36 months
Monthly vesting period after the initial 25% vest on March 28, 2025
Key Terms
Rule 10b5-1 trading plan, stock option, weighted-average price, vests 25%
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option financial
"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
weighted-average price financial
"The reported securities were sold in multiple transactions at prices ranging from"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
vests 25% financial
"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AVTX’s chief financial officer report on September 16, 2026?
The chief financial officer of AVTX exercised 12,394 stock options at $9.88 per share and sold 12,394 common shares at a weighted-average price of $16.33 per share on September 16, 2026.
Was the AVTX insider trading activity done under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2026.
What option exercise price did the AVTX chief financial officer pay?
The option exercise involved 12,394 shares of Avalo Therapeutics common stock at an exercise price of $9.88 per share.
How many Avalo Therapeutics options does the AVTX chief financial officer hold after this transaction?
After the reported option exercise, the chief financial officer held 83,848 stock options to purchase Avalo Therapeutics common stock, according to the filing.
What is the vesting schedule for the AVTX stock option involved in this Form 4?
The stock option vests 25% on March 28, 2025, with the remainder vesting in equal monthly installments over 36 months, subject to the reporting person’s continued service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
